Inventiva, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ritu Baral from TD Cowen maintained a Buy rating on the stock and has a €10.00 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ritu Baral has given her Buy rating due to a combination of factors, including Inventiva’s strong financial position and the promising progress of its Phase 3 NATIV3 MASH trial. The company ended the first half of 2025 with a substantial cash reserve of €122.1 million, bolstered by additional proceeds from a structured financing deal and milestone payments, which extends its operational runway to the third quarter of 2026.
The ongoing Phase 3 trial for lanifibranor in MASH patients is a pivotal study with significant enrollment completed, and topline data is expected in the second half of 2026. The trial’s design, including stratification by fibrosis stage and diabetic status, and the inclusion of patients on stable GLP-1 therapy, enhances the robustness of the study. These strategic financial and clinical advancements underpin Baral’s positive outlook on Inventiva’s stock.
Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of 0RNK in relation to earlier this year.